LinkGevity featured in Financial Times global longevity series
LinkGevity has been profiled in the Financial Times as part of its five-part global series on companies shaping the future of longevity science.
The article highlights LinkGevity’s pioneering Anti-Necrotic technology, which is opening new frontiers in medicine, with potential applications for systemic healthspan regeneration.
The piece features expert perspectives from leading figures in the field. Dr Fenna Sillé of the Johns Hopkins Bloomberg School of Public Health described LinkGevity’s approach as “a very powerful insight into the cascade of damaging events that lead eventually to ageing”- linking environmental, genetic, and biological drivers of decline.
Dr Annalisa Jenkins, biopharma thought leader, noted that LinkGevity’s models of accelerated ageing “create a unique opportunity to test therapies that could protect vulnerable patients in real-world clinical settings.”
LinkGevity’s research builds on the Blueprint Theory of Ageing, developed by Dr Carina Kern alongside Professor Justin Stebbing, and other experts in medicine and longevity, positioning the company at the forefront of a new generation of systemic therapeutics.
